Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Rifampicin, itraconazole, clarithromycin, midazolam, alfentanil and digoxin PBPK models #208

NinaHanke opened this Issue Aug 5, 2018 · 0 comments


None yet
2 participants
Copy link

NinaHanke commented Aug 5, 2018

Dear all,

We have been working on models for DDI prediction, building a small network of interacting CYP3A4 and P-gp index perpetrator and victim drugs. Six whole-body PBPK models (rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, digoxin) were carefully developed and then evaluated by prediction of a multitude of clinical DDI studies.

The corresponding manuscript, including comprehensive documentation, has been accepted for publication in CPT: PSP and the models as well as PK-Sim projects presenting the predicted DDI studies have been uploaded as Open Systems Pharmacology repositories to GitHub (tags: osp-model, ddi, pk-sim, pbpk).

Related publication:
Hanke N, Frechen S, Moj D, Britz H, Eissing T, Wendl T, Lehr T. PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil and digoxin. CPT Pharmacometrics Syst Pharmacol 2018 [accepted for publication].

I would be very happy if some of you find these models useful.
All models can be found here.


Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
You can’t perform that action at this time.